Portfolio company
Herantis Pharma
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
This clinical-stage biotechnology company develops neurorestorative drug therapies for patients living with Parkinson's disease.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Aspen Neuroscience
This biotechnology firm develops personalised autologous cell therapies to replace damaged neurons in patients with Parkinson's disease.
Yumanity Therapeutics
This company develops small molecule drugs to treat neurodegenerative diseases for patients with conditions such as Parkinson's disease and amyotrophic lateral sclerosis.
Neumirna Therapeutics
This biotechnology company develops microRNA-based therapies to treat patients with neurological disorders, including drug-resistant epilepsy and Parkinson's disease.
NeurOdys Therapeutics
This biotechnology company develops small molecule therapies for patients with neurodegenerative conditions such as Alzheimer's and Parkinson's diseases.
CuraSen Therapeutics
This biopharmaceutical company develops small molecule drugs to treat patients with neurodegenerative disorders, such as Parkinson's and Alzheimer's disease.
Teitur Trophics
This company develops neuroprotective peptide therapies for patients suffering from neurodegenerative diseases, including Parkinson's disease, Huntington's disease, and frontotemporal dementia.
Mitokinin
This biotechnology company develops small molecule drugs to treat Parkinson's disease and other neurodegenerative conditions for patients and healthcare providers.
Lario Therapeutics
This company develops precision medicines for patients with severe neurological disorders, including epilepsy and Parkinson’s disease.